Spots Global Cancer Trial Database for pv
Every month we try and update this database with for pv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Assess SLN124 in Patients With Polycythemia Vera | NCT05499013 | Polycythemia Ve... | SLN124 Placebo | 18 Years - | Silence Therapeutics plc | |
| Study to Assess SLN124 in Patients With Polycythemia Vera | NCT05499013 | Polycythemia Ve... | SLN124 Placebo | 18 Years - | Silence Therapeutics plc | |
| A Phase 1 Study of XL019 in Adults With Polycythemia Vera | NCT00595829 | Polycythemia Ve... | XL019 | 18 Years - | Exelixis | |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors | NCT05853458 | Polycythemia Ve... | Hydroxyurea | 18 Years - 99 Years | Novartis | |
| A Phase 1 Study of XL019 in Adults With Polycythemia Vera | NCT00595829 | Polycythemia Ve... | XL019 | 18 Years - | Exelixis | |
| Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera | NCT01243073 | Essential Throm... Polycythemia Ve... | Imetelstat | 18 Years - | Geron Corporation | |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | NCT02410551 | Myeloproliferat... | Pacritinib Busulfan Questionnaires Phone Calls Allogeneic Stem... Fludarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | NCT01632904 | Polycythemia Ve... | Ruxolitinib Hydroxyurea (HU... HU-placebo Ruxolitinib-pla... | 18 Years - | Incyte Corporation | |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | NCT01632904 | Polycythemia Ve... | Ruxolitinib Hydroxyurea (HU... HU-placebo Ruxolitinib-pla... | 18 Years - | Incyte Corporation | |
| A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera | NCT05210790 | Polycythemia Ve... | Placebo Rusfertide | 18 Years - | Protagonist Therapeutics, Inc. | |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | NCT01632904 | Polycythemia Ve... | Ruxolitinib Hydroxyurea (HU... HU-placebo Ruxolitinib-pla... | 18 Years - | Incyte Corporation | |
| Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders | NCT00433862 | Polycythemia Ve... Essential Throm... Idiopathic Myel... Neutrophils Chronic Myelopr... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera | NCT05853445 | Polycythemia Ve... | Jakavi | 18 Years - 120 Years | Novartis | |
| Dasatinib in Polycythemia Vera | NCT00538980 | Polycythemia Ve... | Dasatinib | 18 Years - | Weill Medical College of Cornell University | |
| CINC424A2X01B Rollover Protocol | NCT02386800 | Primary Myelofi... Polycythemia Ve... Graft Versus Ho... Acute Myeloid L... Thalassemia | ruxolitinib panobinostat | 1 Month - | Novartis | |
| Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders | NCT00433862 | Polycythemia Ve... Essential Throm... Idiopathic Myel... Neutrophils Chronic Myelopr... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Dasatinib in Polycythemia Vera | NCT00538980 | Polycythemia Ve... | Dasatinib | 18 Years - | Weill Medical College of Cornell University | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera | NCT03287245 | Polycythemia Ve... | Idasanutlin | 18 Years - | Hoffmann-La Roche | |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors | NCT05853458 | Polycythemia Ve... | Hydroxyurea | 18 Years - 99 Years | Novartis | |
| A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera | NCT05210790 | Polycythemia Ve... | Placebo Rusfertide | 18 Years - | Protagonist Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
